Abstract
Sodium-glucose cotransporter 2 inhibitor tofogliflozin is a new type of antidiabetic drug for individuals with type 2 diabetes mellitus (T2DM). The aim of this study was to examine in which type of individuals and/or under which conditions tofogliflozin could exert more beneficial effects on body composition and/or glycemic control in Japanese individuals with T2DM. We retrospectively evaluated the effects of tofogliflozin on body composition and/or glycemic control in individuals with T2DM who newly started taking tofogliflozin. After tofogliflozin treatment, body weight was significantly reduced and HbA1c levels were significantly decreased. Body fat mass, skeletal muscle mass, and skeletal muscle index, a marker for sarcopenia, were also reduced after the treatment. In univariate analyses, there was a statistically significant association between the decrease of HbA1c level after tofogliflozin treatment (Δ HbA1c) and the following parameters such as HbA1c levels at baseline, visceral fat area (VFA) at baseline, and reduction of VFA after the treatment (Δ VFA). Furthermore, in multivariate analyses, HbA1c levels at baseline and duration of diabetes were independently associated with Δ HbA1c. These results suggest that tofogliflozin would be more suitable for relatively obese individuals whose duration of diabetes is relatively short.
Highlights
SGLT2 inhibitors improved glycemic control by reducing filtered renal glucose reabsorption from the proximal tubule and promoting excretion of excess glucose [1,2,3,4,5]
180 g/day of glucose is filtered by the kidneys every day, but about 90% of such glucose is reabsorbed by SGLT2 in the proximal renal tubule [6,7,8,9]
To evaluate the effects of tofogliflozin on body composition, we evaluated it by using InBody
Summary
SGLT2 inhibitors improved glycemic control by reducing filtered renal glucose reabsorption from the proximal tubule and promoting excretion of excess glucose [1,2,3,4,5]. It has been shown that SGLT2 inhibitors reduce glucose reabsorption in the kidney and increase urinary glucose excretion, which leads a substantial additional calorie loss. It has been well established that SGLT2 inhibitors have effects on weight reduction due to calorie loss [10]. Such effect is one of the ideal benefits of SGLT inhibitors within the framework of diabetes treatment.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
